Trillium Therapeutics Inc (TRIL)

[jondoeuk]

I was thinking more along the lines of lack of tissue distribution and/or side-effects in the ongoing Phase I. After all IT injections will rule out a number of types and patients. Unless they plan to conduct a similar trial as NW Bio did with DCVax-Direct.

As for a combo of Anti-CD47 and Anti-PD1 then I can't see this being the hole grail as downregulation of MHC class I expression is a widespread phenomenon used by tumour cells to escape anti-tumor T-cell mediated immune responses. Then there are other checkpoints http://www.ncbi.nlm.nih.gov/pubmed/26883990 mutations http://www.nejm.org/doi/full/10.1056/NEJMoa1604958#t=article and possible lack of costimulation and other things to keep in mind.

Also M2's aren't the only immunosuppressive cells in a tumour. There are Tregs and MDSCs as well. Then there is tumour derived lactate and stromal density which can help with immune evasion too.